CEFPODOXIME PROXETIL

Post-LOE

cefpodoxime proxetil

Novartis

ANDAORALTABLET1 Generic Approved

Approved

May 2008

Lifecycle

Post-LOE

Competitive Pressure

45/100

Data completeness

4/8 — Partial

CEFPODOXIME PROXETIL (cefpodoxime proxetil) by Novartis is mechanism of action cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Approved for development of drug-resistant bacteria, maintain the effectiveness of cefpodoxime proxetil tablets, other antibacterial drugs and 3 more indications. First approved in 2008.

Drug data last refreshed Yesterday

$0.0BPart D

Mechanism of Action

Mechanism of Action Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.

Indications (6)

development of drug-resistant bacteria maintain the effectiveness of cefpodoxime proxetil tablets

Worked on CEFPODOXIME PROXETIL at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.